Saturday 17 October 2026 Export ELV’s income statement to Excel — free account

Elevance Health, Inc.

Elevance Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $199.1 billion, up 12.5% from fiscal 2024. In the quarter to June 2026, revenue grew 1.40%, EPS fell 13.1%, free cash flow fell 9.01% and total debt rose 4.08%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

428.26 0.17 −0.04%

Follow ELV

Alert me

Market cap: $92.9B
P/E: 19.0×
Fwd P/E: 20.3×
Dividend yield: 1.60%
F-score: 6/9
Altman Z: 3.09
Beneish M: −2.26
Dividend safety: 96/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total buys 2.24

Total sells 1.74

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	—	—	2	—	—	—
Sell	—	—	—	—	2	—	1	2	—	—	—	—

Insider Ownership 0.29%

Capital & Financial Ratios $m

Market Cap 92,910.00

Revenue 201,113.00

Net Income 4,947.00

Free Cash Flow 6,289.00

Net Debt (6,470.00)

Current Ratio 1.52

Debt/Equity 0.69

P/E ratio 19.03

Fwd P/E 20.30

P/S ratio 0.46

P/B ratio 2.06

Past 5Y EPS Growth 6.99%

This Y EPS Growth (10.06%)

Next Y EPS Growth 8.77%

Next Y revenue growth (1.35%)

Next 5Y EPS Growth 3.92%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 77.77%

10-year low 10-year high

P/S against its own 10 years 20.49%

10-year low 10-year high

P/B against its own 10 years 34.39%

10-year low 10-year high

EV/Sales against its own 10 years 26.13%

10-year low 10-year high

EV/FCF against its own 10 years 54.81%

10-year low 10-year high

Dividends

Payout Ratio 0.31

Annual Dividend Rate 6.87

Annual Dividend Yield 1.60%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	6.89	1.72 1.72 1.72
2025	6.84	1.71 1.71 1.71 1.71
2024	6.52	1.63 1.63 1.63 1.63
2023	5.92	1.48 1.48 1.48 1.48
2022	5.12	1.28 1.28 1.28 1.28
2021	4.52	1.13 1.13 1.13 1.13
2020	3.80	0.95 0.95 0.95 0.95
2019	3.20	0.80 0.80 0.80 0.80
2018	3.00	0.75 0.75 0.75 0.75
2017	2.70	0.65 0.65 0.70 0.70
2016	2.60	0.65 0.65 0.65 0.65

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	36,369	34,681	36,115	37,514
Receivables	17,865	19,071	21,542	23,392
Inventory	—	—	—	—
Other	5,795	5,190	5,344	6,278
	60,029	58,942	63,001	67,184

	2023	2024	2025	Q'26
Payables	23,021	22,673	24,406	25,095
ST’ Debt	1,649	1,649	1,099	375
Other	9,894	10,182	10,255	13,681
	41,791	40,581	41,035	44,254

Compound Annual Growth %

	10y	5y	3y
Sales	9.66%	10.32%	8.34%
Cash Flow	0.18%	(16.69%)	(20.06%)
Earnings	8.26%	4.37%	(1.33%)
Book Value	6.69%	5.81%	6.61%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	50,181	50,474	—	—	—
’25	48,891	49,776	50,711	49,747	199,125
’24	42,577	43,886	45,106	45,442	177,011
’23	42,172	43,672	42,849	42,647	171,340
’22	38,095	38,632	39,939	39,929	156,595
’21	32,385	33,851	35,822	36,581	138,639
’20	29,621	29,264	31,158	31,824	121,867

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	4,332	1,913	—	—	—
’25	1,017	2,054	1,135	84	4,290
’24	1,978	447	2,677	706	5,808
’23	6,469	1,950	2,613	(2,971)	8,061
’22	2,541	2,452	4,924	(1,518)	8,399
’21	2,505	1,683	2,504	1,672	8,364
’20	2,515	5,510	(1,150)	3,813	10,688

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	4,097	1,626	—	—	—
’25	821	1,787	775	(209)	3,174
’24	1,699	124	2,345	384	4,552
’23	6,168	1,600	2,294	(3,297)	6,765
’22	2,287	2,157	4,619	(1,816)	7,247
’21	2,301	1,398	2,246	1,332	7,277
’20	2,311	5,277	(1,456)	3,535	9,667

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	8.00	6.71	—	—	—
’25	9.61	7.72	5.32	2.47	25.21
’24	9.59	9.85	4.36	1.81	25.68
’23	8.30	7.79	5.45	3.63	25.22
’22	7.39	6.79	6.68	3.93	24.81
’21	6.71	7.25	6.13	4.63	24.73
’20	5.94	8.91	0.87	2.19	17.98

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	114.85	140.50	215.52	227.16	171.03	286.04	420.73	412.00	362.21	273.71	Analyst estimates 2026–2028 Powerpack
	High	148.26	236.39	300.57	317.99	338.20	470.02	549.52	511.97	567.26	458.75
People
People	Employees	53,000	56,000	63,900	70,600	83,400	98,200	102,300	104,900	104,200	97,100
	Revenue/emp, $m	1.60	1.61	1.44	1.48	1.46	1.41	1.53	1.63	1.70	2.05
Income, $m
Income, $m	Revenue	84,863	90,040	92,105	104,213	121,867	138,639	156,595	171,340	177,011	199,125
	Gross margin, %	21.24	19.77	21.94	19.61	20.41	18.16	17.19	17.34	16.78	14.93
	EBT	4,555	3,964	5,068	5,985	6,238	7,995	7,600	7,715	7,904	6,710
	EBT margin, %	5.37	4.40	5.50	5.74	5.12	5.77	4.85	4.50	4.47	3.37
	Net income	2,470	3,843	3,750	4,807	4,572	6,149	5,888	5,991	5,971	5,661
	Depreciation	912	891	1,132	1,133	1,154	1,302	1,675	1,745	1,393	1,546
Per share, $
Per share, $	Revenue	322.80	344.32	356.86	407.88	485.91	568.66	652.48	726.32	763.97	888.95
	Earnings	9.21	14.35	14.19	18.47	17.98	24.73	24.81	25.22	25.68	25.21
	Cash flow	12.44	16.00	14.83	23.72	42.62	34.31	35.00	34.17	25.07	19.15
	Capex	(2.22)	(3.02)	(4.68)	(4.22)	(4.07)	(4.46)	(4.80)	(5.49)	(5.42)	(4.98)
	Free cash flow	10.22	12.98	10.15	19.51	38.54	29.85	30.20	28.68	19.65	14.17
	Book value	95.48	101.35	110.58	124.18	132.37	148.19	151.38	167.04	178.79	196.54
	Shares, m	263	262	258	256	251	244	240	236	232	224
Valuation, ×
Valuation, ×	P/E	15.55	15.74	18.50	16.38	17.93	18.75	20.26	19.02	14.40	13.96
	P/S	0.44	0.66	0.74	0.74	0.66	0.82	0.77	0.66	0.48	0.39
	P/B	1.50	2.23	2.38	2.43	2.43	3.13	3.32	2.87	2.06	1.78
	EV/Sales	0.34	0.59	0.69	0.68	0.57	0.74	0.70	0.59	0.46	0.37
	EV/FCF	10.85	15.53	24.10	14.23	7.22	14.12	15.19	15.00	17.94	23.41
Cash, $m
Cash, $m	Operating cash flow	3,270	4,185	3,827	6,061	10,688	8,364	8,399	8,061	5,808	4,290
	Capex	(584)	(791)	(1,208)	(1,077)	(1,021)	(1,087)	(1,152)	(1,296)	(1,256)	(1,116)
	Free cash flow	2,686	3,394	2,619	4,984	9,667	7,277	7,247	6,765	4,552	3,174
Balance, $m
Balance, $m	Working capital	13,021	12,907	12,356	15,501	16,298	16,237	15,921	18,238	18,361	21,966
	Total debt	15,287	18,657	18,066	19,385	20,035	22,756	23,849	24,895	30,867	31,896
	Net debt	(8,516)	(6,400)	(4,678)	(6,237)	(10,698)	(10,272)	(10,443)	(11,474)	(3,814)	(4,219)
	Shareholders’ equity	25,100	26,503	28,541	31,728	33,199	36,128	36,330	39,405	41,426	44,026
Returns, %
Returns, %	ROA	3.90	5.67	5.28	6.45	5.57	6.69	5.89	5.66	5.30	4.75
	ROIC	19.89	15.50	15.27	16.51	19.60	21.31	20.40	19.57	15.10	12.74
	ROE	10.26	14.89	13.63	15.95	14.08	17.77	16.27	15.81	14.80	13.25

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
UNH UnitedHealth Group Incorporated	$365.0B	25.8×	23.3×	−0.41% (below 0%: shrinking)	+61.50% (above 0%: growing)	−15.65% (below 0%: shrinking)	100.00%	5.82%	Compare
CVS CVS Health Corporation	$118.4B	24.1×	15.4×	+7.26% (above 0%: growing)	+187.65% (above 0%: growing)	+338.29% (above 0%: growing)	44.52%	4.43%	Compare
ELV Elevance Health, Inc.	$92.9B	19.0×	20.3×	+1.40% (above 0%: growing)	−13.08% (below 0%: shrinking)	−9.01% (below 0%: shrinking)	15.77%	4.56%
CI Cigna Group	$79.0B	12.5×	11.4×	+6.68% (above 0%: growing)	+10.16% (above 0%: growing)	+66.93% (above 0%: growing)	88.24%	3.73%	Compare
HUM Humana Inc.	$51.9B	38.8×	42.9×	+26.18% (above 0%: growing)	+27.88% (above 0%: growing)	+58.51% (above 0%: growing)	13.45%	3.33%	Compare
CNC Centene Corporation	$34.8B	— (loss-making)	24.8×	+9.92% (above 0%: growing)	n/m	+116.61% (above 0%: growing)	8.59%	2.24%	Compare
MOH Molina Healthcare, Inc	$11.1B	— (loss-making)	55.0×	−4.84% (below 0%: shrinking)	−74.95% (below 0%: shrinking)	+5.81% (above 0%: growing)	13.19%	1.33%	Compare
OSCR Oscar Health, Inc.	$10.3B	18.6×	29.7×	+70.40% (above 0%: growing)	n/m	+316.29% (above 0%: growing)	22.25%	7.96%	Compare
CLOV Clover Health Investments, Corp.	$2.5B	— (loss-making)	292×	+55.60% (above 0%: growing)	n/m	+406.43% (above 0%: growing)	20.59%	3.77%	Compare
Median of peers	$43.4B	24.1×	27.3×	+8.59%	+27.88%	+91.77%	21.42%	3.75%

All 12 Healthcare Plans stocks →

Elevance Health, Inc. (ELV) key facts

Concern: Net income was $5.7 billion, or $25.21 per share (basic), a net margin of 2.84%.
Strength: Elevance Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $199.1 billion, up 12.5% from fiscal 2024.
Elevance Health, Inc. (ELV) is a Healthcare Plans company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, ELV traded at $428.26, a market capitalization of $92.9 billion.
At that price the stock trades at 19.0× trailing-twelve-month earnings and 0.5× sales; its P/E is higher than 78% of its own readings over the past ten years.
Elevance Health, Inc. pays an annual dividend of $6.87 per share, a yield of 1.60%, with a payout ratio of 30.5%.
Return on equity was 13.3% and debt-to-equity 0.69.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 3.09 (safe zone) for fiscal 2025.